This level of coordinated buying by a sophisticated biotech investor like ARCH Venture Partners is highly unusual and suggests strong conviction ahead of potential clinical or strategic developments. Traders should watch for upcoming catalysts such as trial readouts, partnerships, or funding news.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 6 $22.46entry
- T+1 · 8mo ago +13.54%α +12.69% · $25.50
- T+5 · 8mo ago −5.39%α −3.86% · $21.25
- T+20 · 8mo ago −3.43%α −1.38% · $21.69
- T+60 · 6mo ago −23.64%α −36.42% · $17.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two funds affiliated with ARCH Venture Partners collectively purchased nearly $25 million worth of Lyell Immunopharma shares in open-market transactions at $25.61 per share. This represents a significant, coordinated investment by a major biotech venture firm, signaling strong confidence in the company's future prospects.
Key Financial Metrics
Key Facts
- ARCH Venture Partners IX, LLC purchased 488,090 shares at $25.61 for $12,500,000
- ARCH Venture Fund XIII, L.P. purchased 488,090 shares at $25.61 for $12,500,000
- Total open-market purchases: $25.0M across two affiliated funds
- Transactions occurred on 2026-03-06 in a single day
- Combined purchase represents approximately 5.2% of Lyell's $477M market cap
Financial Impact
$25.0 million in insider buying, equivalent to 5.2% of market capitalization
Risk Factors
- The purchases were made by affiliated funds, not company insiders (executives or directors), so this reflects investor confidence rather than direct management sentiment
- Biotech stocks are inherently volatile and sensitive to clinical trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-LYEL-1773088624224 |
Track record
21 reports on LYEL
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers